miR‑589‑5p is downregulated in prostate cancer and regulates tumor cell viability and metastasis by targeting CCL‑5

Ji, Lü; Jiang, Xi; Mao, Fei; Tang, Zhiwang; Zhong, Bing

doi:10.3892/mmr.2019.10334

Cited by 17 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In present study, we unveiled miR-589-5p as the downstream miRNA sponged by LOXL1-AS1 in laryngocarcinoma. MiR-589-5p has been reported as important in suppressing the progression of hepatocellular carcinoma [25], endometrial cancer [26], prostate carcinoma [27], and non-small cell lung cancer [28]. Accordingly, our study also proved that miR-589-5p exerted a inhibitory function in laryngocarcinoma progression.…”

Section: Discussionsupporting

confidence: 75%

LOXL1-AS1 contributes to the proliferation and migration of laryngocarcinoma cells through miR-589-5p/TRAF6 axis

Yao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background LOXL1-AS1 is a long non-coding RNA (lncRNA) that plays crucial roles in various cancers. However, the functional role of LOXL1-AS1 in laryngocarcinoma remains unclear. Thus we planned to probe into the function and underlying mechanism of LOXL1-AS1 in laryngocarcinoma. Methods Gene expression was evaluated in laryngocarcinoma cells using RT-qPCR. The ability of cell proliferation and migration was assessed by CCK8, colony formation, wound healing and transwell assays. The interaction among LOXL1-AS1, miR-589-5p and TRAF6 was detected by Ago2-RIP, RNA pull down and luciferase reporter assays. Results LOXL1-AS1 was overexpressed in laryngocarcinoma cells. Silencing of LOXL1-AS1 suppressed cell proliferation, migration and EMT in laryngocarcinoma. Moreover, miR-589-5p, the downstream of LOXL1-AS1, directly targeted TRAF6 in laryngocarcinoma. Importantly, LOXL1-AS1 augmented TRAF6 expression in laryngocarcinoma cells by sequestering miR-589-5p. Besides, miR-589-5p worked as a tumor-inhibitor while TRAF6 functioned as a tumor-facilitator in laryngocarcinoma. Of note, rescue experiments both in vitro and in vivo validated that LOXL1-AS1 aggravated the malignancy in laryngocarcinoma by targeting miR-589-5p/TRAF6 pathway. Conclusions LOXL1-AS1 promotes the proliferation and migration of laryngocarcinoma cells through absorbing miR-589-5p to upregulate TRAF6 expression.

show abstract

Section: Discussionsupporting

confidence: 75%

LOXL1-AS1 contributes to the proliferation and migration of laryngocarcinoma cells through miR-589-5p/TRAF6 axis

Yao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the mechanism of CCL5 in prostate cancer has not been studied very well. Ji et al [29] demonstrated that miR-589-5p regulates prostate cancer cell viability and metastasis by targeting CCL-5. Xiang et al [30] showed that Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling.…”

Section: Discussionmentioning

confidence: 99%

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells

Lin¹,

Lin²,

Lin³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

The diverse tumor cell populations may be the critical roles in relapse and resistance to treatment in prostate cancer patients. This study aimed to identify new marker genes and cell subtypes among castration-resistant prostate cancer (CRPC) cells. We downloaded single-cell RNA seq profiles (GSE67980) from the Gene Expression Omnibus (GEO) database. Principal component (PC) analysis and t-Distributed Stochastic Neighbor Embedding (TSNE) analysis were performed to identify marker genes. CRPC cells were clustered and annotated. GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses among marker genes were performed. A total of 1500 genes with larger standardized variance were obtained. The top 20 genes were demonstrated in each identified 20 PCs. PC with P-value < 0.05 was selected, including PC1, PC7, PC8, and PC14. The TSNE analysis classified cells as two clusters. The top 6 genes in cluster 0 included HBB, CCL5, SLITRK4, GZMB, BBIP1, and PF4V1. Plus, the top 6 genes in cluster 1 included MLEC, CCT8, CCT3, EPCAM, TMPRSS2, EIF4G2. The GO analysis revealed that these marker genes were mainly enriched in RNA catabolic process, translational initiation, mitochondrial inner membrane, cytosolic part, ribosome, cell adhesion molecule binding, cadherin binding, and structural constituent of ribosome. The KEGG analysis showed that these marker genes mainly enriched in metabolism associated pathways, including carbon metabolism, cysteine and methionine metabolism, propanoate metabolism, pyruvate metabolism, and citrate cycle pathways. To conclude, our results provide essential insights into the spectrum of cellular heterogeneity within human CRPC cells. These marker genes, GO terms and pathways may be critical in the development and progression of human CRPC.

show abstract

“…In the vast majority of human cancer types, miR-589-5p was reported to be down-regulated and function as a tumor-suppressive miRNA, including endometrial carcinoma [14], prostate cancer [15], non-small cell lung cancer [16] and acute myeloid leukemia [17]. However, in the HCC context, several lines of evidence have reported that miR-589-5p was remarkably upregulated in clinical HCC tissues, and overexpression of miR-589-5p signi cantly contributed to the progression and aggressiveness of HCC to varying mechanisms [11,12].…”

Section: Discussionmentioning

confidence: 99%

Identification of miR-589-5p as a Potential Prognostic Biomarker of Hepatocellular Carcinoma

Yao¹,

Jiang²,

Weng³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) are small endogenous non-coding RNAs with 22 nucleotides approximately. Numerous studies have reported that microRNAs may hold the potential to serve as biomarkers in diagnosing cancer and predicting prognosis. miR-589-5p is a well-documented oncogenic miRNA implicated in several human cancer types. However, the potential value of miR-589-5p as a biomarker to facilitate early diagnosis and predict prognosis in hepatocellular carcinoma (HCC) patients remains obscure.Methods: miR-589-5p expression was examined by in situ hybridization (ISH) in 10 adjacent normal tissues (ANT), 21 liver fibrosis tissues, 113 HCC tissues, including 22 HCC with grade I, 37 HCC with grade II, 49 HCC with grade III and 5 hepatocholangiocellular carcinoma tissues. Statistical analysis and Kaplan–Meier survival analysis was performed to evaluate the clinical correlation between miR-589-5p expression and clinicopathological features and survival prognosis in HCC patients.Results: miR-589-5p expression was dramatically upregulated in HCC tissues by in situ hybridization (ISH). Overexpression of miR-589-5p was not only positively correlated with poor tumor differentiation degree, increased AFP levels, advanced clinical stage, distant metastatic status and venous invasion, but also predicted poor overall and relapse-free survival in HCC patients. Importantly, the expression levels of miR-589-5p measured by real-time PCR in high-ISH scores tissues were dramatically upregulated compared with those in low-ISH scores tissues, and a strong and positive correlation of miR-589-5p expression levels in real-time PCR with ISH staining index was demonstrated in HCC tissues.Conclusion: our results support the notion that miR-589-5p might hold a promising value as a novel biomarker to facilitate early diagnosis and predict prognosis in HCC patients.

show abstract

miR‑589‑5p is downregulated in prostate cancer and regulates tumor cell viability and metastasis by targeting CCL‑5

Cited by 17 publications

References 42 publications

LOXL1-AS1 contributes to the proliferation and migration of laryngocarcinoma cells through miR-589-5p/TRAF6 axis

LOXL1-AS1 contributes to the proliferation and migration of laryngocarcinoma cells through miR-589-5p/TRAF6 axis

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells

Identification of miR-589-5p as a Potential Prognostic Biomarker of Hepatocellular Carcinoma

Contact Info

Product

Resources

About